VIVUS Inc

VIVUS — Technical Presentation (September 2009)

36 slides from VIVUS's technical presentation, Sep 9, 2009

  1. Slide 1: EQUIP & CONQUER Study Results

    EQUIP & CONQUER Study Results September 9, 2009 Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com VIVUS

  2. Slide 2: Forward-looking statements

    VIVUS cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests,“ "assuming," "designed" and similar exp

  3. Slide 3: Today's Speakers

    Today’s Speakers Leland Wilson, President & CEO Dr. Wesley Day, VP Clinical Development Michelle Look, MD, FAAFP, San Diego Sports Medicine and Family Health Center and principal investigator Peter Tam, Chief Operating Officer VIVUS Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com

  4. Slide 4: Qnexa: EQUIP Summary

    Qnexa: EQUIP Summary EQUIP (OB-302) 1,267 morbidly obese patients Weight loss 14.7% or 37 lbs Full and Low Dose satisfied FDA efficacy benchmarks Improvement in cardio-metabolic risk factors VIVUS Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com

  5. Slide 5: Qnexa: CONQUER Summary

    Qnexa: CONQUER Summary CONQUER (OB-303) 2,487 obese patients with co-morbidities Full Dose-Weight loss 13.2% or 30 lbs Mid Dose-Weight loss 10.5% or 24 lbs Full and Mid Dose satisfied FDA efficacy benchmarks Improvement in cardio-metabolic risk factors VIVUS Copyright © 2009 VIVUS Inc. All rights re

  6. Slide 6: Qnexa: Proprietary Treatment for Obesity

    Qnexa: Proprietary Treatment for Obesity Once a day oral controlled release formulation of low dose phentermine and topiramate 0 400 mg 200 100 300 50 150 250 350 Topiramate 0 30 mg 15 5 10 25 3.75 7.5 Phentermine Maximum Approved Doses 20 23 46 92 Low Mid Full VIVUS Copyright © 2009 VIVUS Inc. All

  7. Slide 7: EQUIP: Morbidly Obese Subjects Study Design

    EQUIP: Morbidly Obese Subjects Titration (4 weeks) Treatment (52 weeks) Study Visits: Every other week during titration Monthly thereafter Qnexa Full Dose (n=512) Qnexa Low Dose (n=241) Placebo (n=514) EQUIP (OB-302) BMI>35 (n=1,267) Study Design VIVUS Copyright © 2009 VIVUS Inc. All rights reserved

  8. Slide 8: EQUIP: Baseline Demographics

    EQUIP: Baseline Demographics 19% History of Dyslipidemia 25% History of Hypertension Baseline Age 43 Female 83% Baseline BMI 42.1 Weight (lbs) 256 Waist Circumference (in) 48 Blood Pressure (mmHg) 122/77 Total Cholesterol (mg/dL) 194 History of Psychiatric Disorders 26% VIVUS Copyright © 2009 VIVUS

  9. Slide 9: EQUIP: High Completion Rates

    Statistically greater number of patients completing study on Qnexa vs. placebo, p<0.0001 498 97% 234 97% 498 97% ITT Population1 (% of randomized) Patients Placebo Qnexa Low Qnexa Full Randomized 514 241 512 Completers2 (% of randomized) 241 47% 138 57%* 301 59%* 1 ITT Population = randomized patien

  10. Slide 10: EQUIP: Primary Efficacy Endpoints

    EQUIP: Primary Efficacy Endpoints Satisfies FDA Efficacy Benchmarks at Both Doses ITT-LOCF Placebo (n=498) Qnexa Low (n=234) Qnexa Full (n=498) Percent weight loss 1.6% 5.1%* 11.0%* % Patients > 5% weight loss 17% 45%* 67%* *p<0.0001 vs. placebo VIVUS Copyright © 2009 VIVUS Inc. All rights reserved.

  11. Slide 11: EQUIP: Continuing Weight Loss Over Time

    EQUIP: Continuing Weight Loss Over Time Completers* Lost 14.7% Body Weight *data from patients that completed 56 weeks on treatment - Qnexa Low -7.0%, 18 lbs - Placebo -2.5%, 6 lbs - Qnexa Full -14.7%, 37 lbs % Weight Loss Weeks -16 -12 -8 -4 0 0 8 16 24 32 40 48 56 VIVUS Copyright © 2009 VIVUS Inc.

  12. Slide 12: EQUIP: Significant Categorical Weight Loss at Both Doses

    EQUIP: Significant Categorical Weight Loss at Both Doses % of Patients with: >15% wt loss PBO 5% Qnexa Low 11%* Qnexa Full 43%** >10% wt loss PBO 12% Qnexa Low 27%** Qnexa Full 60%** >5% wt loss PBO 26% Qnexa Low 59%** Qnexa Full 84%** Completers **p<0.0001 vs placebo *p=0.026 vs placebo Weight Loss

  13. Slide 13: EQUIP: Improved Cardiovascular Risk Factors

    EQUIP: Improved Cardiovascular Risk Factors <0.0001 0.0148 Total Cholesterol/HDL Ratio <0.0001 ns Triglycerides 0.0157 ns LDL 0.0005 ns HDL <0.0001 <0.0001 Waist Circumference 0.0014 0.05 Total Cholesterol ns 0.002 p-value* Qnexa Low CV Risk Factors Qnexa Full p-value* Systolic BP <0.0001 Diastolic

  14. Slide 14: EQUIP: Efficacy Summary

    EQUIP: Efficacy Summary 14.7% (37 lbs) weight loss on Qnexa Full Dose* Qnexa Full and Low doses satisfied FDA efficacy benchmarks Improvement shown for all cardiovascular risk factors * Completer analysis VIVUS Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com

  15. Slide 15: CONQUER: Co-morbid Obese Subjects Study Design

    CONQUER: Co-morbid Obese Subjects Titration (4 weeks) Treatment (52 weeks) Study Visits: Every other week during titration Monthly thereafter Qnexa Full Dose (n=995) Qnexa Mid Dose (n=498) Placebo (n=994) CONQUER (OB-303) BMI = 27-45 with two or more co-morbidities (n=2,487) Study Design VIVUS Copyr

  16. Slide 16: CONQUER: Baseline Demographics

    CONQUER: Baseline Demographics 69% History of Hypertension 57% History of Dyslipidemia 16% History of Diabetes Baseline Age 51 Female 70% Baseline BMI 36.6 Weight (lbs) 227 Waist Circumference (in) 44.5 Blood Pressure (mmHg) 128/81 Total Cholesterol 205 Fasting Blood Glucose (mg/dL) 106 History of P

  17. Slide 17: CONQUER: High Completion Rates

    CONQUER: High Completion Rates Patients Placebo Qnexa Mid Qnexa Full Randomized 994 498 995 ITT Population1 (% of randomized) 979 99% 488 98% 981 99% Completers2 (% of randomized) 564 57% 344 69%* 634 64%* Statistically greater number of patients completed study on Qnexa vs. placebo, p<0.0001 1 ITT

  18. Slide 18: CONQUER: Primary Efficacy Endpoints

    CONQUER: Primary Efficacy Endpoints Satisfies FDA Efficacy Benchmarks at Both Doses ITT-LOCF Placebo (n=979) Qnexa Mid (n=488) Qnexa Full (n=981) Percent weight loss 1.8% 8.4%* 10.4%* % Patients > 5% weight loss 21% 62%* 70%* *p<0.0001 vs. placebo VIVUS Copyright © 2009 VIVUS Inc. All rights reserve

  19. Slide 19: CONQUER: Weight Loss Over Time

    - Qnexa Mid -10.5%, 24 lbs - Qnexa Full -13.2%, 30 lbs CONQUER: Weight Loss Over Time Completers* Lost 13.2% Body Weight *data from patients that completed 56 weeks on treatment **based upon BMI goal of 30 73% excess weight lost ** - Placebo -2.4%, 6 lbs Weeks % Weight Loss -16 -12 -8 -4 0 0 8 16 24

  20. Slide 20: CONQUER: Significant Categorical Weight Loss at Both Doses

    CONQUER: Significant Categorical Weight Loss at Both Doses % of Patients with: >15% wt loss PBO 4% Qnexa Mid 26%** Qnexa Full 39%** >10% wt loss PBO 10% Qnexa Mid 49%** Qnexa Full 64%** >5% wt loss PBO 26% Qnexa Mid 75%** Qnexa Full 85%** Completers **p<0.0001 vs placebo Weight Loss 0 10 20 30 40 50

  21. Slide 21: CONQUER: Improved Cardiovascular Risk Factors

    CONQUER: Improved Cardiovascular Risk Factors <0.0001 0.0345 Total Cholesterol <0.0001 <0.0001 Triglycerides 0.0069 ns LDL <0.0001 <0.0001 HDL <0.0001 <0.0001 Waist Circumference <0.0001 <0.0001 Total Cholesterol/ HDL Ratio ns <0.0001 p-value Qnexa Mid Risk Factors Qnexa Full p-value Systolic BP <0.

  22. Slide 22: CONQUER: Improved Diabetes Risk Factors

    CONQUER: Improved Diabetes Risk Factors <0.0001 <0.0001 OGTT Insulin <0.0001 0.0047 Fasting Blood Glucose <0.0001 <0.0001 Hemoglobin A1c <0.0001 0.0007 Insulin Resistance (HOMA) p-value Qnexa Mid Risk Factors Qnexa Full p-value p-values represent comparisons to placebo ITT-LOCF Placebo Comparisons V

  23. Slide 23: CONQUER: Improved Inflammatory Risk Factors

    CONQUER: Improved Inflammatory Risk Factors <0.0001 <0.0001 CRP <0.0001 <0.0001 Adiponectin 0.048 0.023 Fibrinogen p-value Qnexa Mid Risk Factors Qnexa Full p-value p-values represent comparisons to placebo ITT-LOCF Placebo Comparisons VIVUS Copyright © 2009 VIVUS Inc. All rights reserved. | www.viv

  24. Slide 24: CONQUER: Decreased BP in Obese Hypertensive Patients

    CONQUER: Decreased BP in Obese Hypertensive Patients (Subgroup Analysis) *p<0.0001 vs. placebo Baseline SBP 146.0 146.2 146.8 * SBP (mmHg) Reduction in htn meds Increase in htn meds -13.6 -20.4 -15.6 -25 -20 -15 -10 -5 0 SBP Change at Week 56 (upper quartile) Placebo Qnexa Mid Qnexa Full VIVUS Copyr

  25. Slide 25: CONQUER: Decreased Triglyceride in Obese Dyslipidemic Patients

    CONQUER: Decreased Triglyceride in Obese Dyslipidemic Patients (Subgroup Analysis) *p<0.0001 vs placebo Baseline: 262 260 268 * * Triglycerides (mg/dL) -42 -98 -95 -120 -100 -80 -60 -40 -20 0 Total Triglycerides Change at Week 56 (upper quartile) Placebo Qnexa Mid Qnexa Full VIVUS Copyright © 2009 V

  26. Slide 26: CONQUER: Decreased HbA1c in Obese Diabetic Patients

    CONQUER: Decreased HbA1c in Obese Diabetic Patients (Subgroup Analysis) *p<0.0001 vs. placebo Rates of hypoglycemia were comparable to placebo (<0.5%) Baseline: 7.4% 7.1% 7.3% Hemoglobin A1c (%) * * -0.1 -0.6 -0.5 -0.7 -0.6 -0.5 -0.4 -0.3 -0.2 -0.1 0.0 HbA1c Change at Week 56 (upper quartile) Placeb

  27. Slide 27: CONQUER: Efficacy Summary

    CONQUER: Efficacy Summary 13.2% (30 lbs) weight loss on Qnexa Full Dose* 10.5% (24 lbs) weight loss on Qnexa Mid Dose* Both doses exceed FDA efficacy benchmarks Clinically meaningful improvement in cardiovascular, diabetes and inflammatory risk factors compared to placebo Patients at higher risk exp

  28. Slide 28: Treatment-Emergent Adverse Events >5%: EQUIP & CONQUER

    Treatment-Emergent Adverse Events >5%: EQUIP & CONQUER 4.8 3.8 3.0 5.1 3.3 3.5 Cough 5.4 5.2 3.7 4.7 3.3 3.5 Urinary Tract Infection 6.0 4.0 3.6 4.5 6.3 3.1 Blurred Vision 5.2 4.4 4.3 5.5 6.7 4.3 Bronchitis EQUIP (N=1,264) CONQUER (N=2,485) % of Patients (N=3,749) Placebo Qnexa Low Qnexa Full Placeb

  29. Slide 29: Low Discontinuation Rate in All Doses Studied

    Low Discontinuation Rate in All Doses Studied 1.2% 0.8% 0.8% 0.1% Irritability 0.7% 0.8% 2.1% 0.5% Blurred Vision 0.8% 1.2% 0.4% 0.2% Dizziness 0.9% 0.2% 1.7% 0.7% Headache 1.7% 0.4% 0.0% 0.4% Insomnia 1.4% 0.8% 0.0% 0.2% Depression 1.2% 1.0% 0.4% 0.0% Tingling 1.1% 0.2% 0.0% 0.3% Anxiety 18% 12% 12

  30. Slide 30: EQUIP & CONQUER: Depression Assessment

    EQUIP & CONQUER: Depression Assessment 1.9% 1.2% 1.7% 1.7% Moderate or severe AEs Depression/Depressed Mood Qnexa Full Qnexa Mid Qnexa Low Placebo No difference between Qnexa and placebo for incidence of moderate or severe depression/depressed mood No serious adverse events (SAE) reported for depres

  31. Slide 31: Patient Health Questionnaire (PHQ-9)

    Patient Health Questionnaire (PHQ-9) PHQ-9 is a validated tool for diagnosing and assessing severity of depression. 38,000 PHQ-9 assessments taken in EQUIP and CONQUER Conclusion: No signal for depression Significant improvement in depression scores VIVUS Copyright © 2009 VIVUS Inc. All rights reser

  32. Slide 32: EQUIP & CONQUER: Suicidality Assessments

    EQUIP & CONQUER: Suicidality Assessments C-SSRS (Columbia Suicide Severity Rating Scale) developed to assess suicidality Over 38,000 C-SSRS assessments taken in EQUIP and CONQUER Results: No suicides No suicide attempts No suicidal behavior No signal for suicidal ideation Conclusion: No signal for s

  33. Slide 33: Overall Safety Assessments

    Overall Safety Assessments Serious Adverse Event Assessment (EQUIP & CONQUER) Total SAE not different between Qnexa (3.3%) and placebo (3.3%) Drug Related SAE not different between Qnexa (0.4%) and placebo (0.4%) One death on placebo Cognitive Function Studies completed, no clinically relevant effec

  34. Slide 34: Quality of Life and Health & Physical Function

    Quality of Life and Health & Physical Function Impact of Weight on Quality of Life (IWQOL) Significant improvement in (ITT-LOCF vs. placebo) : Quality of Life Self-Esteem Public Distress Physical Function Work Score Sexual Life Score Short Form Health Survey (SF-36) Significant improvement in (ITT-L

  35. Slide 35: What can a hypothetical at-risk patient expect from Qnexa?

    What can a hypothetical at-risk patient expect from Qnexa? Typical At-risk Patient 51 year old female 250 lbs Hypertension (BP: 147/92 mmHg) Diabetes (HbA1c: 7.3%) HDL: 33 mg/dL LDL: 171 mg/dL TG: 268 mg/dL Framingham 10-yr CHD risk: 27% After 1 year on Qnexa Lost 37 lbs Normal (BP: 126/81 mmHg) Bel

  36. Slide 36: Qnexa: EQUIP and CONQUER Summary

    Qnexa: EQUIP and CONQUER Summary Unprecedented weight loss 14.7% (37 lbs)* Clinically meaningful improvements across cardiovascular, metabolic and inflammatory risk factors All three doses of Qnexa exceeded FDA efficacy benchmarks Well tolerated with completion rates significantly higher than placeb

VIVUS — Technical Presentation (September 2009) on 6ix